

Maria Ximena Rojas Reyes

'Authors election'

Author statement- MXRojas

María Ximena Rojas. Cochrane Colombia. S.A.

- Why you wish to run for a position on the Cochrane Council

During these three years in the council, I have been able to learn more about the operation of the organization and have always sought that the community of authors be taken into account in pivotal decisions of the organization. Always seeking to know the opinions of authors, for which I have worked to achieve direct and effective communication channels to the extent that the organization has allowed me.

For a second term, My first aim is to contribute in the development of strategies to support authors to complete their reviews with high quality methodological level, particularly to those authors from non- English speakers' countries. I am sure there is an important human capacity for developing high quality SR that could be involved to give its contribution to the Collaboration.

- What skills, experience, or qualities you would bring to Council

I think I will be an effective member of the council as an author representative because my current experience as health professional and within the Collaboration. I have been involved in evidence based medicine and knowledge translation in health for the last 18 years. I am an active member of several groups within the Collaboration; I have been involved as author for more than 14 years, and as advisor member of GRADEing methods and Economic Methods groups for at least 6 years.

- Acknowledge that you are aware of the commitment required to participate

For this period, I will have greater availability of time from my work for completing council tasks and the advantage of prior knowledge of council procedures, to continue bringing the voice of the authors to the directives of the collaboration and especially, looking for the community of authors to be considered and favored with the government decisions.

- A list of the Cochrane Review(s) on which you have an Author role.

Active reviews

- *Rescue high-frequency jet ventilation versus conventional ventilation for severe pulmonary dysfunction in preterm infants*
- *Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants*

- *Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants*
- *Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease*
- *Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants*

Protocols

- *Overview of ventilation strategies for the early management of intubated preterm infants (submitted for editorial process)*
- *Oral xanthine derivatives (theophylline and doxofylline) for patients with stable chronic obstructive pulmonary disease (COPD)*
- *Once-daily LABA/ICS combined inhalers versus inhaled long-acting beta2-agonists for people with chronic obstructive pulmonary disease (COPD)*
- *Protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome in neonates*

Reviews Withdrawn because were considered no priority reviews by the review group

- *Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children*
- *Oxygen therapy for lower respiratory tract infections in children between 3 months and 15 years of age*